Mizuho Securities USA LLC Raises Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Mizuho Securities USA LLC raised its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 46.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,014 shares of the medical equipment provider's stock after buying an additional 6,952 shares during the period. Mizuho Securities USA LLC's holdings in Hologic were worth $1,587,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. General Partner Inc. acquired a new position in Hologic during the 4th quarter worth $26,000. Groupama Asset Managment raised its stake in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after buying an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC raised its position in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after acquiring an additional 261 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 134 shares during the period. Finally, EverSource Wealth Advisors LLC raised its holdings in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on HOLX shares. Royal Bank of Canada cut their price objective on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research report on Thursday, February 6th. Wolfe Research started coverage on shares of Hologic in a report on Friday, December 13th. They set a "peer perform" rating for the company. Needham & Company LLC lowered shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target on the stock. in a research note on Monday, February 3rd. Evercore ISI reduced their price objective on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. Finally, Jefferies Financial Group started coverage on Hologic in a research report on Tuesday, December 10th. They issued a "hold" rating and a $85.00 target price on the stock. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $84.62.

Hologic Trading Down 1.6 %

Shares of HOLX traded down $1.00 during trading hours on Friday, hitting $61.32. 1,110,999 shares of the stock were exchanged, compared to its average volume of 1,809,690. Hologic, Inc. has a fifty-two week low of $60.34 and a fifty-two week high of $84.67. The business has a 50-day moving average of $65.24 and a 200-day moving average of $73.29. The firm has a market capitalization of $13.76 billion, a P/E ratio of 19.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.